Abstract:Background: Cell loss and mitochondrial dysfunction are key pathological features of idiopathic Parkinson's disease (PD) and multiple system atrophy (MSA). It remains unclear whether disease-specific changes in plasma circulating cell-free nuclear DNA (cf-nDNA) and mitochondrial DNA (cf-mtDNA) occur in patients with PD and MSA. In this study, we investigated whether plasma cf-nDNA, cf-mtDNA levels, as well as cf-mtDNA integrity, are altered in patients with PD and MSA. Methods: TaqMan probe-based quantitative PCR was employed to measure plasma cf-nDNA levels, cf-mtDNA copy numbers, and cf-mtDNA deletion levels in 171 participants, including 76 normal controls (NC), 62 PD patients, and 33 MSA patients. A generalized linear model was constructed to analyze differences in circulating cell-free DNA (cfDNA) biomarkers across clinical groups, while a logistic regression model was applied to assess the predictive values of these biomarkers for developing PD or MSA. Spearman correlations were used to explore associations between the three cfDNA biomarkers, demographic data, and clinical scales. Results: No significant differences in plasma cf-nDNA levels, cf-mtDNA copy numbers, or cf-mtDNA deletion levels were observed among the PD, MSA, and NC groups (all P > 0.05). Additionally, these measures were not associated with the risk of developing PD or MSA. In PD patients, cf-nDNA levels were positively correlated with Hamilton Anxiety Rating Scale scores (Rho = 0.382, FDR adjusted P = 0.027). In MSA patients, cf-nDNA levels were positively correlated with International Cooperative Ataxia Rating Scale scores (Rho = 0.588, FDR adjusted P = 0.011) and negatively correlated with Montreal Cognitive Assessment scores (Rho = −0.484, FDR adjusted P = 0.044). Subgroup analysis showed that PD patients with constipation had significantly lower plasma cf-mtDNA copy numbers than those without constipation ( P = 0.049). MSA patients with cognitive impairment had significantly higher cf-nDNA levels compared to those without ( P = 0.008). Conclusion: Plasma cf-nDNA level, cf-mtDNA copy number, and cf-mtDNA deletion level have limited roles as diagnostic biomarkers for PD and MSA. However, their correlations with clinical symptoms support the hypothesis that cell loss and mitochondrial dysfunction are involved in PD and MSA development.

No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts

The association between plasma GPNMB and Parkinson's disease and multiple system atrophy

No Association of GPNMB Rs156429 Polymorphism with Parkinson’s Disease, Amyotrophic Lateral Sclerosis and Multiple System Atrophy in Chinese Population

CSF GPNMB in Parkinson's disease: A potential association with age and microglial activation

Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Cross-Sectional Study

Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study

The Association Analysis of GPNMB Rs156429 with Clinical Manifestations in Chinese Population with Parkinson's Disease

Probing the diagnostic values of plasma cf-nDNA and cf-mtDNA for Parkinson's disease and multiple system atrophy

Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis

Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting

Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease

Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy

Increase of the Plasma Α‐synuclein Levels in Patients with Multiple System Atrophy

Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy.

Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis

Elevated serum growth differentiation factor 15 in multiple system atrophy patients: A case control study

Corneal confocal microscopy may help to distinguish Multiple System Atrophy from Parkinson’s disease

Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson's disease

Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease

SNP Rs11931074 of Thesncagene May Not Be Associated with Multiple System Atrophy in Chinese Population

Monocytohigh-density lipoprotein ratio has a high predictive value for the diagnosis of multiple system atrophy and the differentiation from Parkinson's disease